SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001689813-22-000014
Filing Date
2022-02-25
Accepted
2022-02-25 16:38:46
Documents
136
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K bhvn-20211231.htm   iXBRL 10-K 3494479
2 EX-10.41 a2021bhvnex1041engelhartde.htm EX-10.41 57202
3 EX-10.42 a2021bhvnex1042sixthstreet.htm EX-10.42 70109
4 EX-21.1 a202110-kbhvnexhibit211.htm EX-21.1 10047
5 EX-23.1 a202110-kbhvnexhibit231.htm EX-23.1 4104
6 EX-23.2 a202110-kbhvnexhibit232.htm EX-23.2 2115
7 EX-31.1 a202110-kbhvnexhibit311.htm EX-31.1 10525
8 EX-31.2 a202110-kbhvnexhibit312.htm EX-31.2 10739
9 EX-32.1 a202110-kbhvnexhibit321.htm EX-32.1 7601
15 bhvn-20211231_g1.jpg GRAPHIC 23128
16 bhvn-20211231_g2.jpg GRAPHIC 85295
17 bhvn-20211231_g3.jpg GRAPHIC 4121346
18 bhvn-20211231_g4.jpg GRAPHIC 3649480
19 bhvn-20211231_g5.jpg GRAPHIC 92148
20 bhvn-20211231_g6.jpg GRAPHIC 63048
  Complete submission text file 0001689813-22-000014.txt   33932477

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bhvn-20211231.xsd EX-101.SCH 125339
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bhvn-20211231_cal.xml EX-101.CAL 146843
12 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bhvn-20211231_def.xml EX-101.DEF 664312
13 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bhvn-20211231_lab.xml EX-101.LAB 1332017
14 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bhvn-20211231_pre.xml EX-101.PRE 1007059
130 EXTRACTED XBRL INSTANCE DOCUMENT bhvn-20211231_htm.xml XML 2707688
Mailing Address 215 CHURCH STREET NEW HAVEN CT 06510
Business Address 215 CHURCH STREET NEW HAVEN CT 06510 203-404-0410
Biohaven Pharmaceutical Holding Co Ltd. (Filer) CIK: 0001689813 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38080 | Film No.: 22680917
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences